Khronicheskiy gastrit: kak preodolet' kompleks neopredelennosti?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Discovery of the role of Helicobacter pylori as a major etiologic factor in the development of chronic gastritis (CG) has led to the creation of new ideas on the clinical and morphological features of the disease. Pathogenetic relationship between CG and duodenal ulcer, MALT-lymphoma of the stomach and gastric cancer is firmly established; numerous therapies are developed. Unfortunately, debates on the topic “Is this microbe pathogen or saprophyte, or what are the differences between CG and functional dyspepsia?" are continued in our scientific literature. Such a complex of uncertainty in terms of CG leads to the high prevalence of the CG in Russia and the not always effective and timely treatment of this disease. The article reveals the pathogenic nature of CG and its role in the mechanisms of gastric carcinogenesis. Variants of prognosis in natural history of the disease are discussed; the basic algorithms of its diagnosis and treatment are presented.

Full Text

Restricted Access

About the authors

N. M Khomeriki

S. G Khomeriki

References

  1. Marshall B. Helicobacter pylori: уроки прошлого и новые возможности. // Эксперим. и клин. гастроэнтерол. 2008. № 8. С. 6-11.
  2. Булгаков С.А. Еще раз о взаимоотношении диагнозов "хронический гастрит" и "функциональная диспепсия": новые возможности терапевтической коррекции этих расстройств // Фарматека 2012. № 2 (235). С. 51-5.
  3. Хомерики С.Г., Касьяненко В.И. Лабораторная диагностика инфекции Helicobacter pylori. СПб, 2011. 110 с.
  4. Correa P. Helicobacter pylori and gastric carcinogenesis. Am JSurg Pathol 1995;19(1):S37-43.
  5. Rugge M., Genta R.M. Staging and grading of chronic gastritis. Hum Pathol 2005;36:228-33.
  6. Rugge M., de Boni M., Pennelli G., Mescoli C., Graham D.Y. OLGA can guard the barn. Am J Gastroenterol 2009;104(6):3101-102.
  7. Correa P., Piazuelo M. The gastric precancerous cascade. J Dig Dis 2012;13(1):2-9.
  8. Rugge M., Fassan M., Pizzi M., et al. Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol 2011;42(10):1539-44.
  9. Dixon M.F. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut 2001;49:2-4.
  10. Yamada T., Miwa H., Fujino T., et al. Improvement of gastric atrophy after Helicobacter pylori eradication therapy. J Clin Gastroenterol 2003;36:405-10.
  11. Wang J., Xu L., Shi R., et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83:253-60.
  12. Rokkas T., Pistiolas D., Sechopoulos P., et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007;12(2):32-8.
  13. Ito M., Haruma K., Kamada T., et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16: 1449-56.
  14. Toyokawa T., Suwaki K., Miyake Y., et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol 2010;25:544-47.
  15. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
  16. You W.C., Brown L.M., Zhang L., et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
  17. Ahmed N., Sechi L.A. Helicobacter pylori and gastroduodenal pathology: new threats of the old friend. Ann Clin Microbiol Antimicrob 2005;4:1.
  18. Лазебник Л.Б., Хомерики С.Г. Канцеропревенция в гастроэнтерологии // Эксперим. и клин. гастроэнтерол. 2012. № 5. С. 3-13.
  19. Dinis Ribeiro M., Areia M., de Vries A.C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012:44;74-94.
  20. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012: doi:10.1136/ gutjnl-2012-302254.
  21. Sun Q., Liang X., Zheng Q., et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010;15(3):233-38.
  22. Лазебник Л.Б., Васильев Ю.В., Щербаков П.Л. и др. Helicobacter pylori: распространенность, диагностика, лечение // Эксперим. и клин. гастроэнтерол. 2010. № 2. С. 3-7.
  23. Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему // Эксперим. и клин. гастроэнтерол. 2012. № 5. С. 99-106.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies